Berlin’s pandemic preparedness contracts are complicating BioNTech’s planned closure of its German COVID-19 vaccine production sites. The federal health ministry confirmed that 7.6 million doses of Comirnaty LP.8.1 still sit in the central warehouse, and no further deliveries are due. But the real tension lies in the standby agreements Germany holds with BioNTech, IDT Biologika and Wacker/Corden Pharma — contracts that require domestic manufacturing capacity for future crises. BioNTech intends to shift all future vaccine production to Pfizer facilities in Europe and the Americas, prompting the ministry to warn it will examine whether the company can still meet its contractual obligations.
The stock already reflects this transitional uncertainty. On Wednesday, BioNTech shares traded at €75.95, down 0.98% on the day and 10.65% over the past month. Over twelve months, the shares have shed roughly 25% of their value, and they remain more than 28% below the 52-week high of €105.80.
At the ASCO congress, BioNTech showcased the clinical rationale for its oncology pivot. Lead candidate pumitamig, a bispecific antibody targeting PD-L1 and VEGF-A, is being tested in the global phase 3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer. Co-developed with Bristol Myers Squibb, the study uses progression-free survival as the single primary endpoint, with overall survival as a key secondary — a regulatory shortcut Özlem Türeci said should allow earlier talks with authorities once PFS data are available. Interim phase 2 data were encouraging: in squamous tumours the confirmed objective response rate reached 68.4%, with a disease control rate of 100% across 40 evaluable patients. Non-squamous disease posted a 57.1% ORR.
BioNTech’s pipeline now spans more than 25 phase 2 and phase 3 studies, 13 of which are considered registration-relevant. The financial cost of this transformation is steep. First-quarter revenue slid to €118.1 million from €182.8 million a year earlier, and the net loss stood at €531.9 million. Still, the company holds €16.8 billion in cash and maintains full-year guidance of €2.0 billion to €2.3 billion in revenue.
Should investors sell immediately? Or is it worth buying BioNTech?
Management is backing that balance sheet strength with a buyback programme of up to $1.0 billion, confirmed in May. Analysts remain split. Bernstein initiated coverage on 22 May with a Market Perform rating and a $96 price target, cautioning that the clinical expansion is broad but near-term share price upside appears limited. Jefferies is more bullish with a Buy rating and $138 target, though analyst Akash Tewari noted that early oncology data in NSCLC have yet to show clear differentiation from competing drug Ivonescimab, and any long-term edge will depend on new combination strategies.
The biggest strategic shift comes at the top. Founders Ugur Sahin and Özlem Türeci plan to exit management by the end of 2026 to lead a new independent mRNA research company, with BioNTech expected to retain a minority stake. The separation aligns with a broader restructuring: research on one side, late-stage development and commercialisation on the other.
The next hard test is the PFS readout from ROSETTA Lung-02. A convincing result would give BioNTech the data anchor for early regulatory dialogues. Without strong late-stage proof, the oncology strategy remains ambitious but unproven — and the debate in Berlin over production capacity is unlikely to quieten while the transformation plays out.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from June 3 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 3.
BioNTech: Buy or sell? Read more here...
